eLetters

103 e-Letters

published between 2006 and 2009

  • Comments on the paper by Smith et al.
    Jacob M. van Laar

    Dear Editor,

    I read with interest the article by Smith et al, which provides encouraging data on safety and potential efficacy of rituximab in a subset of patients with diffuse cutaneous systemic sclerosis (DcSSc). It lends support to the concept that B-cell depletion could be a relatively safe and effective strategy DcSSc. The effects on skin thickening differ from those published by Lafyatis et al, indicating a prospec...

    Show More
  • Oliver Distler

    Dear Editor,

    We thank Dres Arends and Fadini and their coworkers for their interest in our article and for their comments.

    In general, the EUSTAR recommendations are guidelines for research in an evolving field. We fully agree with the statements by Dres Arends and Fadini that these recommendations should not be considered as a final and definite, but should rather be seen as a first attempt to reach conse...

    Show More
  • Infliximab Dose Escalation: the Final Word?
    Rene Westhovens

    Dear Editor,

    We read with interest the recent article by Pavelka and colleagues [1] and the accompanying editorial by van Vollenhoven [2] regarding dose escalation of infliximab in the treatment of patients with rheumatoid arthritis (RA). Pavelka and colleagues evaluated infliximab dose escalation in patients who had initially responded (based on the criteria of an improvement of 1.2 in the 28-joint count Disease Activ...

    Show More
  • Autoantibodies to PDGF receptor and systemic sclerosis
    Jean-Baptiste Demoulin

    Dear Editor,

    While the debate on the existence of autoantibodies against the PDGF receptor is amplified by two publications (1, 2) that contradict the data published by Gabrielli and colleagues (3), we wish to point to one important detail in the paper of Balada et al (4).

    The protein that is sold by Upstate biologicals (now Millipore) and was used in the assay developed by Balada and colleagues corresponds to t...

    Show More
  • Methotrexate, the gold standard?
    Cornelia F. Allaart

    Dear editor,

    The editorial of colleagues Kay and Westhovens on the 3 E project about use of methotrexate makes some excellent points on the position of methotrexate in our daily practice, especially in the first 2 paragraphs.
    The fact that apparently methotrexate remains the initial preferred antirheumatic drug rests on perceived efficacy, an acceptable safety profile, and maybe predominantly on low...

    Show More
  • Azathioprine: An explanation for the risk of skin SCC among patients with Crohn’s disease?
    Ioannis D. Bassukas

    Dear editor

    We read with interest the recent metaanalysis by Burmester et al1 on the spectrum of adverse events that were recorded among the participants of global adalimumab clinical trials. However, the observed increased risk of Crohn’s disease (CD) patients to develop a skin squamous cell carcinoma (SCC) compared to base-line and to other adalimumab-treated patients is quite important to deserve an additional comment...

    Show More
  • Paracetamol and the placebo effect in osteoarthritis trials. The missing link
    henning zeidler, MD

    Dear Editor,

    Zhang and colleagues reported in a recent metaanalysis of randomised trials that placebo is very effective in the treatment of osteoarthritis (OA), especially for pain, stiffness and self-reported function.[1] In addition Zhang et al. concluded:” Important determinants of the magnitude of effect appear to be the baseline severity, the expected strength of the treatment, the route of delivery and the sample...

    Show More
  • EUSTAR’s statement and recommendations on endothelial precursor cells – putting things into perspect
    Steven Jonathan Arends

    Dear Editor,

    The European League Against Rheumatism Scleroderma Trials and Research (EUSTAR) group provided recommendations for standardization of future research on endothelial progenitor cells (EPCs)[1]. We support this initiative, as the use of different protocols by different study groups in EPC research hampers substantial advancement in this field. However, we feel that some of the statements made by the EUSTAR gr...

    Show More
  • Comment on the viewpoint by P Emery et al, “Guidelines for initiation of anti TNF treatment in RA"
    JE Fonseca

    Dear Sir,

    We read with great interest the viewpoint written by P Emery et al entitled “Guidelines for initiation of antitumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe”.(1)
    The Portuguese Society of Rheumatology issued its guidelines for the use of antitumour necrosis factor (anti-TNF) therapy in rheumatoid arthritis (RA) for the first time in 2003....

    Show More
  • Anti-inflammatory effects of statin
    Rizaldy Pinzon

    Dear Editor,

    This review is very interesting. This review showed some evidence about the relationship between RA and cardiovascular risk. Statins are the most widely prescribed drugs, used for the treatment of hypercholesterolemia and resulting cardiovascular diseases. Previous reports showed that mechanism by which statins may reduce vascular event rates relates to potential anti-inflammatory effects of these agents....

    Show More

Pages